Renal Cell Carcinoma

SAN FRANCISCO — In this video, Toni K. Choueiri, MD, gives a summary of a subgroup analysis of the KEYNOTE-564 study he presented at the annual ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — In this video, Toni K. Choueiri, MD, highlights a biomarker analysis of CheckMate 9ER he presented at the annual ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — Healio spoke with Toni K. Choueiri, MD, about follow-up data from the CheckMate 9ER presented at ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — In this video, Toni K. Choueiri, MD, who was the senior author, discusses an analysis of COSMIC-313 presented at ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — In this video, Meredith M. Regan, ScD, discusses a study she presented at the annual ASCO Genitourinary Cancers Symposium that assessed treatment-free survival outcomes among patients with advanced clear cell renal cell carcinoma.

SAN FRANCISCO — Nivolumab plus cabozantinib extended OS and PFS compared with sunitinib as first-line treatment for patients with advanced renal cell carcinoma, according to updated results of the randomized phase 3 CheckMate 9ER trial.

Thromboembolism incidence appeared high among patients who received immunotherapy-based combinations for metastatic renal cell carcinoma, according to retrospective study results.

The addition of a cell-based immune primer to sunitinib exhibited activity among patients with metastatic renal cell carcinoma, according to randomized phase 2 study results.

Tivozanib improved long-term PFS compared with sorafenib among patients with relapsed or refractory advanced renal cell carcinoma, according to study results.

Most patients with renal cell carcinoma ineligible for surgery and ablation achieved tumor reduction after treatment with nivolumab plus ipilimumab, according to study results.